Boston Scientific announces results for second quarter 2026

Boston Scientific announces results for second quarter 2026 MARLBOROUGH, Mass., July 29, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.442 billion during the second quarter of 2026, growing 7.5 percent on a reported basis and 7.0 percent on an operational 1 and organic 2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $907 million or $0.61 per share (EPS), compared to $797 million or $0.53 per share a year ago, and achieved adjusted 3 EPS of $0.86 for the period, compared to $0.75 a year ago.

"Our team delivered a solid quarter while continuing to navigate a dynamic environment," said Mike Mahoney, chairman and chief executive officer, Boston Scientific. "We are focused on disciplined execution and prioritizing investments in our highest-impact opportunities, and we remain confident in Boston Scientific's long-term growth, anchored by our category leadership strategy and our commitment to meaningful innovation for patients and physicians."

Second quarter financial results and recent developments:

Operational net sales growth excludes the impact of foreign currency fluctuations.

Organic net sales growth excludes the impact of foreign currency fluctuations and net sales attributable to certain acquisitions and divestitures for which there are less than a full period of comparable net sales.

Adjusted EPS excludes the impact of certain charges (credits) as defined below within the "Use of Non-GAAP Financial Measures" section.

The SIEGEL Balloon Expandable TAVR system, the SEISMIQ 4CE Coronary Intravascular Lithotripsy Catheter and the FARAFLEX Mapping and PFA Catheter are investigational devices. Limited by Federal (or U.S.) law to investigational use only. Not available for sale.

Net sales for the second quarter by business and region:

Increase/(Decrease)

Three Months Ended

June 30,

Reported

Basis

Impact of

Foreign

Currency

Fluctuations

Operational

Basis

Impact of

Certain

Acquisitions

/Divestitures

Organic

Basis

(in millions)

2026

2025

Endoscopy

$ 793

$ 737

7.6 %

(0.7) %

7.0 %

— %

7.0 %

Urology

684

676

1.1 %

(0.3) %

0.8 %

— %

0.8 %

Neuromodulation

341

303

12.7 %

(0.6) %

12.2 %

— %

12.2 %

MedSurg

1,818

1,716

5.9 %

(0.5) %

5.4 %

— %

5.4 %

Cardiovascular

3,624

3,345

8.3 %

(0.6) %

7.8 %

— %

7.8 %

Net Sales

$ 5,442

$ 5,061

7.5 %

(0.5) %

7.0 %

— %

7.0 %

Increase/(Decrease)

Three Months Ended

June 30,

Reported

Basis

Impact of

Foreign

Currency

Fluctuations

Operational

Basis

(in millions)

2026

2025

U.S.

$ 3,426

$ 3,224

6.2 %

— %

6.2 %

EMEA

932

878

6.1 %

(1.9) %

4.2 %

APAC

878

790

11.2 %

(0.0) %

11.2 %

LACA

206

169

22.4 %

(6.2) %

16.2 %

Net Sales

$ 5,442

$ 5,061

7.5 %

(0.5) %

7.0 %

Amounts may not add due to rounding. Growth rates are based on actual, non-rounded amounts and may not recalculate precisely.

Net sales growth rates that exclude the impact of foreign currency fluctuations and/or the impact of certain acquisitions/divestitures are not

prepared in accordance with U.S. GAAP.

Guidance for Full Year and Third Quarter 2026

The company now estimates net sales growth for the full year 2026, versus the prior year period, to be approximately 5.5 to 6.5 percent on a reported basis and 5 to 6 percent on an organic basis. Full year organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to certain acquisitions and divestitures for which there are less than a full period of comparable net sales. The company now estimates adjusted EPS, excluding certain charges (credits), of $3.28 to $3.32.

The company estimates net sales growth for the third quarter of 2026, versus the prior year period, to be approximately 3 to 5 percent on a reported and organic basis. Third quarter organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to certain acquisitions and divestitures for which there are less than a full period of comparable net sales. The company estimates adjusted EPS, excluding certain charges (credits), of $0.80 to $0.82.

The company has not provided reconciliations of the forward-looking adjusted EPS guidance to GAAP guidance as it is unable to predict with reasonable certainty and without unreasonable efforts the impact of certain items such as intangible asset impairment charges, acquisition-related charges, restructuring and restructuring-related charges and litigation-related charges. The combined impact of these items is uncertain, dependent on various factors and cannot be predicted with reasonable certainty, and could be material to our GAAP measures of financial results.

Conference Call Information

Boston Scientific management will be discussing these results with analysts on a conference call today at 8:00 a.m. ET. The company will webcast the call to interested parties through its website: investors.bostonscientific.com. Please see the website for details on how to access the webcast. The webcast will be available for approximately one year on the Boston Scientific website.

About Boston Scientific

Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at www.bostonscientific.com and follow us on LinkedIn.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "may," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our expected net sales; reported, operational and organic revenue growth rates; adjusted EPS for the third quarter and full year 2026; our financial performance; acquisitions; clinical trials; our business plans and product performance; and new and anticipated product approvals and launches. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Risks and uncertainties that may cause such differences include, among other things: economic conditions, including the impact of foreign currency fluctuations; future U.S. and global political, competitive, reimbursement and regulatory conditions, including changing trade and tariff policies; geopolitical conflicts and tensions; manufacturing, distribution and supply chain disruptions and cost increases; disruptions caused by cybersecurity events; disruptions caused by public health emergencies or extreme weather or other climate change-related events; labor shortages and increases in labor costs; variations in outcomes of ongoing and future clinical trials and market studies; new product introductions; expected procedural volumes; the closing and integration of acquisitions; demographic trends; intellectual property; litigation; financial market conditions; the execution and effect of our business strategy, including our cost-savings and growth initiatives; and future business decisions made by us and our competitors. New risks and uncertainties may arise from time to time and are difficult to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements, except as required by law. This cautionary statement is applicable to all forward-looking statements contained in this press release.

Note: Amounts reported in millions within this press release are computed based on the amounts in thousands. As a result, the sum of the components reported in millions may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying unrounded amounts.

Use of Non-GAAP Financial Information

A reconciliation of the company's non-GAAP financial measures to the corresponding GAAP measures, and an explanation of the company's use of these non-GAAP financial measures, is included in the exhibits attached to this press release.

CONTACT:

‌

Media:

Chanel Hastings

Investors:

Lauren Tengler

508-382-0288 (office)

508-683-4479 (office)

Media Relations

Investor Relations

Boston Scientific Corporation

[email protected]

BOSTON SCIENTIFIC CORPORATION

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

Three Months Ended

June 30,

‌

Six Months Ended

June 30,

(in millions, except per share data)

2026

2025

2026

2025

Net sales

$ 5,442

$ 5,061

$ 10,646

$ 9,724

Cost of products sold (excluding amortization expense)

1,594

1,637

3,184

3,090

Gross profit

3,848

3,424

7,462

6,633

Operating expenses:

Selling, general and administrative expenses

1,803

1,716

3,583

3,312

Research and development expenses

554

526

1,069

969

Royalty expense

Amortization expense

233

225

466

444

Intangible asset impairment charges

—

Contingent consideration net expense (benefit)

(16)

(5)

(46)

Restructuring net charges (credits)

Litigation-related net charges (credits)

—

2,670

2,605

5,183

4,894

Operating income (loss)

1,178

819

2,279

1,740

Other income (expense):

Interest expense

(96)

(90)

(186)

(172)

Other, net

(23)

213

129

179

Income (loss) before income taxes

1,060

941

2,222

1,746

Income tax expense (benefit)

155

146

(21)

279

Net income (loss)

905

795

2,243

1,467

Net income (loss) attributable to noncontrolling interests

(2)

(4)

Net income (loss) attributable to Boston Scientific common stockholders

$ 907

$ 797

$ 2,247

$ 1,471

Net income (loss) per common share - basic

$ 0.62

$ 0.54

$ 1.52

$ 0.99

Net income (loss) per common share - diluted

$ 0.61

$ 0.53

$ 1.51

$ 0.98

Weighted-average shares outstanding

Basic

1,470.2

1,479.9

1,477.6

1,478.5

Diluted

1,474.8

1,493.5

1,484.9

1,493.3

Amounts may not add due to rounding.

BOSTON SCIENTIFIC CORPORATION

NON-GAAP NET INCOME AND NET INCOME PER SHARE RECONCILIATIONS

(Unaudited)

Three Months Ended June 30, 2026

(in millions, except per share data)

Gross

Profit

Operating

Expenses

Operating

Income

(Loss)

Other

Income

(Expense)

Income

(Loss)

Before

Income

Taxes

Net

Income

(Loss)

Net Income

(Loss)

Attributable to

Noncontrolling

Interests

Net Income

(Loss)

Attributable to

Boston

Scientific

Common

Stockholders

Impact

per

Reported

$ 3,848

$ 2,670

$ 1,178

$ (118)

$ 1,060

$ 905

$ (2)

$ 907

$ 0.61

Non-GAAP adjustments:

Amortization expense

—

(233)

233

—

233

206

203

0.14

Acquisition/divestiture-related net

charges/credits

(61)

—

0.05

Restructuring and restructuring-related net

charges/credits

(16)

—

0.02

Litigation-related net charges/credits

—

(76)

—

0.04

Investment portfolio net losses/gains and

impairments

—

(2)

—

(2)

(0.00)

EU MDR implementation costs

(3)

—

0.00

IEEPA tariff refund

(83)

—

(83)

—

(83)

(77)

—

(77)

(0.05)

Deferred tax expenses/benefits

—

0.05

Adjusted

$ 3,824

$ 2,281

$ 1,543

$ (120)

$ 1,423

$ 1,275

$ 1

$ 1,275

$ 0.86

Three Months Ended June 30, 2025

(in millions, except per share data)

Gross

Profit

Operating

Expenses

Operating

Income

(Loss)

Other

Income

(Expense)

Income

(Loss)

Before

Income

Taxes

Net

Income

(Loss)

Net Income

(Loss)

Attributable to

Noncontrolling

Interests

Net Income

(Loss)

Attributable to

Boston

Scientific

Common

Stockholders

Impact

per

Reported

$ 3,424

$ 2,605

$ 819

$ 122

$ 941

$ 795

$ (2)

$ 797

$ 0.53

Non-GAAP adjustments:

Amortization expense

—

(225)

225

—

225

193

191

0.13

Goodwill and other intangible asset impairment

charges

—

(46)

—

0.02

Acquisition/divestiture-related net

charges/credits

(92)

138

(230)

(92)

—

(92)

(0.06)

Restructuring and restructuring-related net

charges/credits

(124)

161

—

161

142

—

142

0.10

Investment portfolio net losses/gains and

impairments

—

(2)

—

(2)

(0.00)

EU MDR implementation costs

(3)

—

0.01

Deferred tax expenses/benefits

—

0.03

Discrete tax items

—

0.00

Adjusted

$ 3,514

$ 2,114

$ 1,399

$ (110)

$ 1,289

$ 1,127

$ 0

$ 1,127

$ 0.75

An explanation of the company's use of these non-GAAP financial measures is provided at the end of this document.

Amounts may not add due to rounding.

BOSTON SCIENTIFIC CORPORATION

NON-GAAP NET INCOME AND NET INCOME PER SHARE RECONCILIATIONS

(Unaudited)

Six Months Ended June 30, 2026

(in millions, except per share data)

Gross

Profit

Operating

Expenses

Operating

Income

(Loss)

Other

Income

(Expense)

Income

(Loss)

Before

Income

Taxes

Net

Income

(Loss)

Net Income

(Loss)

Attributable to

Noncontrolling

Interests

Net Income

(Loss)

Attributable to

Boston

Scientific

Common

Stockholders

Impact

per

Reported

$ 7,462

$ 5,183

$ 2,279

$ (57)

$ 2,222

$ 2,243

$ (4)

$ 2,247

$ 1.51

Non-GAAP adjustments:

Amortization expense

—

(466)

466

—

466

410

406

0.27

Acquisition/divestiture-related net

charges/credits

(118)

175

(36)

139

103

—

103

0.07

Restructuring and restructuring-related net

charges/credits

(29)

—

0.05

Litigation-related net charges/credits

—

(76)

—

0.04

Investment portfolio net losses/gains and

impairments

—

(139)

(106)

—

(106)

(0.07)

EU MDR implementation costs

(5)

—

0.01

IEEPA tariff refund

(83)

—

(83)

—

(83)

(77)

—

(77)

(0.05)

Deferred tax expenses/benefits

—

(250)

—

(250)

(0.17)

Adjusted

$ 7,492

$ 4,490

$ 3,002

$ (232)

$ 2,771

$ 2,465

$ 1

$ 2,464

$ 1.66

Six Months Ended June 30, 2025

(in millions, except per share data)

Gross

Profit

Operating

Expenses

Operating

Income

(Loss)

Other

Income

(Expense)

Income

(Loss)

Before

Income

Taxes

Net

Income

(Loss)

Net Income

(Loss)

Attributable to

Noncontrolling

Interests

Net Income

(Loss)

Attributable to

Boston

Scientific

Common

Stockholders

Impact

per

Reported

$ 6,633

$ 4,894

$ 1,740

$ 6

$ 1,746

$ 1,467

$ (4)

$ 1,471

$ 0.98

Non-GAAP adjustments:

Amortization expense

—

(444)

444

—

444

383

378

0.25

Goodwill and other intangible asset impairment

charges

—

(46)

—

0.02

Acquisition/divestiture-related net

charges/credits

136

(150)

286

(229)

—

0.04

Restructuring and restructuring-related net charges/credits

(149)

210

—

210

184

—

184

0.12

Investment portfolio net losses/gains and

impairments

—

0.00

EU MDR implementation costs

(7)

—

0.01

Deferred tax expenses/benefits

—

0.06

Discrete tax items

—

0.00

Adjusted

$ 6,846

$ 4,097

$ 2,749

$ (216)

$ 2,533

$ 2,249

$ 1

$ 2,248

$ 1.51

An explanation of the company's use of these non-GAAP financial measures is provided at the end of this document.

Amounts may not add due to rounding.

BOSTON SCIENTIFIC CORPORATION

Q3 and FY 2026 GUIDANCE RECONCILIATIONS

(Unaudited)

Net Sales

‌

Q3 2026 Estimate

Full Year 2026 Estimate

(Low)

(High)

(Low)

(High)

Reported growth

3.0 %

5.0 %

5.5 %

6.5 %

Impact of foreign currency fluctuations

— %

(0.5) %

Operational growth

3.0 %

5.0 %

6.0 %

Impact of certain acquisitions/divestitures

— %

Organic growth

3.0 %

5.0 %

6.0 %

Use of Non-GAAP Financial Measures

To supplement our unaudited consolidated financial statements presented on a GAAP basis, we disclose certain non-GAAP financial measures, including adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common stockholders and adjusted net income (loss) per share (EPS) that exclude certain charges (credits); operational net sales, which exclude the impact of foreign currency fluctuations; and organic net sales, which exclude the impact of foreign currency fluctuations as well as the impact of certain acquisitions and divestitures with less than a full period of comparable net sales. These non-GAAP financial measures are not in accordance with generally accepted accounting principles in the United States and should not be considered in isolation from or as a replacement for the most directly comparable GAAP financial measures. Further, other companies may calculate these non-GAAP financial measures differently than we do, which may limit the usefulness of those measures for comparative purposes.

To calculate adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common stockholders and adjusted net income (loss) per share, we exclude certain charges (credits) from GAAP net income and GAAP net income attributable to Boston Scientific common stockholders, which include amortization expense, goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), investment portfolio net losses (gains) and impairments, restructuring and restructuring-related net charges (credits), litigation-related net charges (credits), European Union (EU) Medical Device Regulation (MDR) implementation costs, debt extinguishment net charges, deferred tax expenses (benefits), discrete tax items and other charges (credits) as appropriate. Amounts are presented after-tax using the company's effective tax rate, unless the amount is a significant unusual or infrequently occurring item in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 740-270-30, "General Methodology and Use of Estimated Annual Effective Tax Rate." In addition to the explanation below, please refer to Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission or Part I, Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations in any Quarterly Report on Form 10-Q that we have filed or will file thereafter for an explanation of each of these adjustments and the reasons for excluding each item. The following is an explanation of each incremental or revised adjustment type, since our most recent Annual Report on Form 10-K, that management excluded as part of these non-GAAP financial measures as well as the reason for excluding each item:

The GAAP financial measures most directly comparable to adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common stockholders and adjusted net income (loss) per share are GAAP net income (loss), GAAP net income (loss) attributable to Boston Scientific common stockholders and GAAP net income (loss) per common share – diluted, respectively.

To calculate operational net sales growth rates, which exclude the impact of foreign currency fluctuations, we convert actual net sales from local currency to U.S. dollars using constant foreign currency exchange rates in the current and prior periods. To calculate organic net sales growth rates, we also remove the impact of certain acquisitions and divestitures with less than a full period of comparable net sales. The GAAP financial measure most directly comparable to operational net sales and organic net sales is net sales reported on a GAAP basis.

Reconciliations of each of these non-GAAP financial measures to the corresponding GAAP financial measure are included in the accompanying schedules.

Management uses these supplemental non-GAAP financial measures to evaluate performance period over period, to analyze the underlying trends in our business, to assess our performance relative to our competitors and to establish operational goals and forecasts that are used in allocating resources. In addition, management uses these non-GAAP financial measures to further its understanding of the performance of our operating segments. The adjustments excluded from our non-GAAP financial measures are consistent with those excluded from our operating segments' measures of net sales and profit or loss. These adjustments are excluded from the segment measures reported to our chief operating decision maker that are used to make operating decisions and assess performance.

We believe that presenting adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common stockholders, adjusted net income (loss) per share, operational net sales growth rates and organic net sales growth rates, in addition to the corresponding GAAP financial measures, provides investors greater transparency to the information used by management for its operational decision-making and allows investors to see our results "through the eyes" of management. We further believe that providing this information assists our investors in understanding our operating performance and the methodology used by management to evaluate and measure such performance.

SOURCE Boston Scientific Corporation